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In eight patients, the right ventricular effective refrac•
tory period, rate-«iependent changes in intraventricular 
conduction (as reflected by QRS duration during ven•
tricular paced cycle lengths of 600 to 250 ms) and results 
of programmed ventricular stimulation were determined 
in the control state, 5 minutes after the intravenous in•
fusion of 10 mg/kg body weight of amiodarone and after 
2 months of treatment with oral amiodarone. The right 
ventricular effective refractory period was 230 ± 30 ms 
(mean ± SD) in the control study, 248 ± 27 ms after 
intravenous amiodarone (p < 0.001) and 296 ± 26 ms 
after oral amiodarone (p < 0.001). In the control state, 
QRS duration was constant at all paced cycle lengths. 
Intravenous amiodarone resulted in a rate-dependent 
prolongation ofQRS duration. This rate-dependent pro•
longation was markedly accentuated by oral amiodarone 
in six patients who had an elevated serum level of reverse 
triiodothyronine (T 3) after 2 months of oral treatment, 
but it was not more pronounced than the effects of in•
travenous amiodarone in two patients with a normal 
reverse T 3 serum level after oral therapy. Both intra-
The clinical response and results of programmed ventricular 
stimulation in patients with malignant ventricular arrhyth•
mias treated chronically with oral amiodarone have been 
extensively studied (1-10). Much less information has been 
gathered on the acute effects of intravenous administration 
of amiodarone. Intravenous amiodarone was found to sup•
press ventricular arrhythmias in some studies (11-16), but 
not in others (17,18). It was reported not to prolong ven•
tricular refractoriness significantly in studies (15,18,19) in 
which only a dose of 5 mg/kg body weight was used. One 
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venous and oral amiodarone either suppressed or mod•
ified the induction of ventricular iachycardia by pro•
grammed stimulation in some patients, but in a discordant 
fashion. The relative effects of intravenous and oral 
amiodarone on ventricular refractoriness and conduc•
tion and on ventricular tachycardia induction did not 
correlate with serum amiodarone levels. 
Chronic amiodarone therapy results in a marked pro•
longation in ventricular refractoriness compared with 
the relatively small but significant increase that occurs 
after intravenous amiodarone. Accentuation by oral 
amiodarone of the rate-dependent slowing of intraven•
tricular conduction caused by intravenous amiodarone 
may be related to a direct electrophysiologic effect of 
amiodarone that is potentiated by an amiodarone-in•
duced abnormality in thyroid hormone metabolism. The 
different effects of intravenous and oral amiodarone on 
ventricular tachycardia induction may be explained by 
different relative effects on refractoriness and conduction. 
(J Am Coil CardioI1986;7:148-57) 
prior study (18) compared, in the same patients, the acute 
and chronic effects of amiodarone on ventricular refracto•
riness and ventricular tachycardia induction, but the effects 
on tachycardia were evaluated in only three patients. More•
over, although the rate-dependent effects of amiodarone on 
intraventricular conduction have been studied in relation to 
acute intravenous administration (20), they have not been 
studied in relation to long-term oral administration. 
Some investigators (21,22) have found that the thera•
peutic effects of amiodarone occur within a particular range 
of amiodarone serum levels, while others (23) have reported 
that an elevation in the serum level of reverse triiodothy•
ronine (T3) correlates with amiodarone's therapeutic effect. 
The latter observation led to the suggestion that the effects 
of amiodarone may be at least in part related to the distur•
bance in thyroid hormone metabolism induced by amio-
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darone (24). However, no prior study has examined the 
relation between serum levels of reverse T 3 and amioda•
rone's effects on ventricular refractoriness and conduction 
in humans. 
The aim of the present study was to compare, in the same 
patients, the effects of high dose intravenous (10 mg/kg) 
and long-term oral amiodarone therapy on ventricular re•
fractoriness, intraventricular conduction and ventricular 
tachycardia induction. In addition, the relation among the 
electrophysiologic effects and serum concentrations of 
amiodarone, its principal metabolite (desethylamiodarone) 
and reverse T 3 were examined. 
Methods 
Patient characteristics. The subjects of this study con•
sisted of eight patients: five with recurrent, sustained ven•
tricular tachycardia, two with out-of-hospital cardiac arrest 
and one with recurrent, nonsustained ventricular tachycar•
dia. There were seven men and one woman, with a mean 
age of 61 ± 7 years (± 1 SD). All eight patients had 
coronary artery disease and a remote history of myocardial 
infarction. The mean left ventricular ejection fraction de•
termined by contrast or radionuclide ventriculography was 
0.38 ± 0.13% (range 0.20 to 0.59). Before participation 
in this study, each patient underwent programmed ventric•
ular stimulation and had inducible sustained ventricular 
tachycardia in the drug-free state. Before being treated with 
amiodarone, these patients underwent a mean of 2.8 ± I 
drug trials that were ineffective in controlling ventricular 
tachycardia either clinically or during electropharmacologic 
testing. 
Electrophysiologic testing protocol. After informed 
consent was obtained under a protocol approved by the 
Committee on Human Research at the University of Mich•
igan, the patients were brought to the electrophysiology 
laboratory in the fasting, unsedated state after all antiar•
rhythmic drugs had been discontinued for at least four half•
lives. Two quadripolar electrode catheters were inserted 
percutaneously into a femoral vein and positioned in the 
right ventricular apex and in the outflow tract or at the 
septum. Arterial blood pressure was monitored continuously 
with a 5F cannula inserted percutaneously into a femoral 
artery. Electrocardiographic leads V J, I and III, the right 
ventricular electro grams and arterial blood pressure were 
displayed simultaneously on an oscilloscope and recorded 
at a paper speed of 25 to 150 mrnls with an Electronics for 
Medicine VR-16 recorder. Programmed ventricular stimu•
lation was performed with a programmable stimulator (Bloom 
Associates, Ltd.) using stimuli with a current intensity of 
twice diastolic threshold and a duration of 2 ms. In every 
patient. the diastolic excitability threshold was 0.7 rnA or 
less. 
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Programmed ventricular stimulation was performed ini•
tially at the right ventricular apex with single and double 
extrastimuli at two basic drive cycle lengths (usually 600 
and 400 ms). If sustained ventricular tachycardia was not 
induced, stimulation was repeated at the right ventricular 
septum or outflow tract. This was followed by programmed 
ventricular stimulation with triple extrastimuli at the right 
ventricular apex and then at the second right ventricular site. 
Ventricular tachycardia was defined as sustained if it had 
a duration of at least 30 seconds or required direct current 
countershock for termination. It was defined as nonsustained 
if it had a duration of six beats to 30 seconds. In each patient, 
sustained ventricular tachycardia was induced at least once 
in the control state. In five patients direct current counter•
shock was needed to terminate the tachycardia artd therefore 
this arrhythmia was induced only once before the admin•
istration of amiodarone. In three patients direct current coun•
tershock was not needed and ventricular tachycardia was 
induced at least twice in the baseline state. 
The duration of the QRS complex during ventricular pac•
ing was used as an index of intraventricular conduction. 
Incremental pacing was performed at the right ventricular 
apex at cycle lengths of 600, 500. 400, 350, 300, 275 and 
250 ms for 15 to 20 complexes. The last several complexes 
of each pacing train were recorded at a paper speed of 1 ~O 
mrnls. The effective refractory period at the right ventricular 
apex was then determined at a basic drive cycle length of 
500 ms, immediately before the administration of amiodarone. 
Testing of intravenous amiodarone. Amiodarone was 
administered intravenously in a dose of 10 mg/kg, at a rate 
of 50 mg/min. This resulted in a 10 to 20 mm Hg decrease 
in systolic blood pressure, but no patient developed symp•
tomatic hypotension. The electrode catheter positioned at 
the right ventricular apex was not moved during the period 
of drug infusion. Five minutes after completion of the amio•
darone infusion, determination of the effective refractory 
period at the right ventricular apex was repeated, followed 
by incremental ventricular pacing. The electrocardiographic 
standardization was the same as that used in the initial study. 
Programmed ventricular stimulation was then performed us•
ing a protocol identical to that used before drug adminis•
tration. The end point of the stimulation protocol was the 
induction of sustained ventricular tachycardia. A blood sam•
ple for determination of the serum levels of amiodarone and 
desethylamiodarone was drawn when the stimulation pro•
tocol was completed (15 to 20 minutes after completion of 
the admiodarone infusion). 
Testing of oral amiodarone. Oral amiodarone therapy 
was initiated at a dose of 1,200 mg/day for 5 days, followed 
by 800 mg/day for 1 month and then 600 mg/day for 1 
month. No patient was treated with any other antiarrhythmic 
drug. After a mean of 8.9 ± 1 weeks (range 8 to 10) of 
treatment with amiodarone (mean cumulative dose 46.1 ± 
1.3 g). an electrophysiologic study was repeated. An elec-
150 MORADY ET AL 
INTRA VENOUS VERSUS ORAL AMIODARONE 
JACC Vol 7. No I 
January 1986.148-57 
Table 1. Serum Levels of Amiodarone, Desethylamiodarone and Reverse T3 After Intravenous 
and Oral Amiodarone Administration 
Intravenous Amiodarone Oral Amiodarone 
Amiodarone Reverse T3 Amiodarone Desethylamiodarone Reverse T3 
Case (ltg/ml)* (pg/ml)t (ltg/ml) (ltg/mn (pg/ml)t 
1 3.9 292 1.5 1.2 917 
2 4.2 278 0.9 0.5 515 
3 4.8 318 1.9 1.2 569 
4 2.7 265 3.2 2.6 549 
5 4.1 246 1.9 1.1 557 
6 2.9 340 2.2 1.4 1,545 
7 4.5 280 2.6 2.8 340 
8 3.5 250 1.7 1.2 343 
*Desethylamiodarone was not detected in any patient aiter intravenous amiodarone administration. tNormal 
range 80 to 350 pg/ml. T3 = triiodothyronine. 
trode catheter was positioned in the right ventricular apex 
such that the QRS complexes during ventricular pacing were 
similar in configuration to the paced QRS complexes in the 
baseline study. The right ventricular effective refractory 
period was determined at a basic drive cycle length of 500 
ms and incremental right ventricular pacing was performed 
as in the baseline study to assess the rate-dependent effects 
of oral amiodarone on intraventricular conduction. Pro•
grammed ventricular stimulation was then performed using 
the same protocol as before. The end point of the stimulation 
protocol was one induction of ventricular tachycardia re•
quiring direct current countershock or two or more induc•
tions of sustained ventricular tachycardia that could be ter•
minated by overdrive pacing. Programmed stimulation was 
performed at the same two right ventricular sites as in the 
baseline study. On completion of the electrophysiologic study, 
blood samples were drawn for determination of serum levels 
of amiodarone, desethylamiodarone and reverse T3 (24 to 
28 hours after the last oral dose of amiodarone). 
Data analysis. The electrocardiographic lead with the 
most clearly defined onset and offset of the paced QRS 
complex was used to measure the QRS duration during 
ventricular pacing. The same lead Was used for all mea•
surements in each patient. Patients in whom the onset or 
offset of the QRS complex was not well defined in any of 
the three monitored leads were not included in this study. 
The duration of the last QRS complex of each pacing train 
was measured independently in blinded fashion by two ob•
servers. Intra- and interobserver variability was less than 
5%. 
All statistical comparisons were performed with a paired 
t test. Values are expressed as mean ± 1 SO. 
Results 
Serum levels of amiodarone, desethylamiodarone and 
reverse T 3 (Table 1). The mean serum level of amiodarone 
after intravenous amiodarone administration was 3.8 ± 0.7 
JLg/ml; desethylamiodarone was not detected in any patient. 
After 2 months of treatment with oral amiodarone, the mean 
serum levels of amiodarone and desethylamiodarone were 
2.0 ± 0.7 and 1.5 ± 0.8 JLg/ml, respectively. The baseline 
mean reverse T 3 level was 284 ± 32 pg/ml (normal range 
Table 2. Effects of Intravenous and Oral Amiodarone Administration on Ventricular Refractoriness and Intraventricular Conduction 
RVERP (ms) QRS, PCL 600 ms (ms)* QRS, Min PCL (ms)t Min PCL (ms)* 
Case C IV Oral C IV Oral C IV Oral C IV Oral 
220 230 310 168 181 234 168 207 286 250 250 350 
2 210 240 270 160 164 184 160 208 226 250 250 300 
3 240 260 320 200 227 260 260 255 294 275 275 350 
4 200 210 270 127 127 166 127 160 194 250 250 300 
5 280 290 340 140 147 174 140 160 194 300 350 400 
6 260 270 300 114 114 134 114 140 143 250 275 400 
7 190 220 270 180 183 186 180 220 214 250 250 275 
8 240 260 290 173 193 190 173 227 203 250 275 350 
*QRS duration at a ventricular paced cycle length (PCL) of 600 ms; tQRS duration at the minimal (Min) paced cycle length resulting in complete 
ventricular capture; *minimal paced cycle length resulting in complete ventricular capture. C = control; IV = intravenous; PCL = paced cycle length; 
RVERP = right ventricular effective refractory period. 
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Figure 1. Patient 1. The rate-dependent effects of intravenous and 
chronic oral amiodarone therapy on QRS duration. Shown are the 
last two to three QRS complexes of a train of 15 to 20 paced 
complexes. In the control state, the QRS duration was 168 ms at 
a paced cycle length of both 600 and 250 ms. After intravenous 
amiodarone, QRS duration increased by 8% to 181 ms at a paced 
cycle length of 600 ms and by 23% to 207 ms at a paced cycle 
length of 250 ms. The rate-dependent prolongation in QRS duration 
was markedly accentuated after 2 months of treatment with oral 
amiodarone. At a paced cycle length of 600 ms, QRS duration 
increased by 39% over control (to 234 ms) and increased by 70% 
to 286 ms at a paced cycle length of 350 ms. At paced cycle 
lengths shorter than 350 ms, there was 2: 1 ventricular capture. 
80 to 350). After 2 months of treatment with oral amio•
darone, the mean reverse T J level was 667 ± 397 pg/ml. 
Effects on right ventricular effective refractory period 
(Table 2). The baseline mean right ventricular effective 
refractory period was 230 ± 30 ms. This value increased 
in each patient by 10 to 30 ms to a mean of 248 ± 27 ms 
(p < 0.001) after intravenous amiodarone therapy and in•
creased by 40 to 90 ms over baseline to a mean of 296 ± 
26 ms (p < 0.00 1) after chronic oral therapy. The mean 
ventricular effective refractory period after oral amiodarone 
was significantly greater than after intravenous amiodarone 
(p < 0.001). 
Effects on intraventricular conduction (Table 2). In 
the baseline state, QRS duration was the same at all ven•
tricular paced cycle lengths, and the shortest paced cycle 
length associated with complete ventricular capture was 260 
± 19 ms. After intravenous and oral amiodarone therapy, 
the shortest paced cycle length associated with complete 
ventricular capture was 272 ± 34 ms (p > 0.05 versus 
control) and 341 ± 46 ms (p < 0.001 versus control and 
intravenous admiodarone), respectively. 
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After intravenous amiodarone, there was a rate-depen•
dent increase in QRS duration (Fig. I). At a ventricular 
paced cycle length of 600 ms, QRS duration was unchanged 
compared with the control value (p > 0.05), whereas at a 
paced cycle length of 250 ms, QRS duration increased by 
25 ± 3% (p < 0.001) (Fig. 2). 
After oral amiodarone therapy at a ventricular paced 
cycle length of 600 ms, there was also a rate-dependent 
increase in QRS duration (Fig. 1). The QRS duration in•
creased by 21 ± 12% over the control value (p < 0.01) at 
a ventricular paced cycle length of 600 ms and increased 
by 42 ± 20% (p < 0.05) at a paced cycle of 350 ms (Fig. 
2). At the shortest cycle length associated with complete 
ventricular capture, the QRS duration after oral amiodarone 
was increased by 39 ± 18% over the pre-drug value (p < 
0.01 ). The increment over control in QRS duration at the 
shortest paced cycle length associated with complete ven•
tricular capture was not significantly greater after oral amio•
darone (39 ± 18%) than after intravenous amiodarone (24 
± 5%, P > 0.05). At paced cycle lengths of 600,500 and 
400 ms, the magnitude of change in the QRS duration com•
pared with control was greater after oral than after intra•
venous amiodarone (p < 0.05) (Fig. 2). Examining the 
relative effects of intravenous and oral amiodarone on QRS 
duration, the effect of oral amiodarone was more pro•
nounced in six patients (Cases 1 to 6) and not more pro•
nounced in two patients (Cases 7 and 8, Fig. 3). 
Effects on ventricular tachycardia induction. The 
configuration and cycle length of ventricular tachycardia 
induced in the control study are described in Table 3. After 
intravenous amiodarone, ventricular tachycardia became 
nonsustained in one patient and noninducible in two patients 
(Fig. 4). In these two patients (Cases I and 6), the coupling 
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Figure 2. The rate-dependent effects of intrave-
60 nous and chronic oral amiodarone therapy on QRS 
duration. Shown is the percent change (compared (f) a:::: 
with control) in the QRS duration at ventricular 0 
paced cycle lengths of 600 to 250 ms. Above each z 
bar is shown 1 standard deviation. The numbers I-t 
in parentheses refer to the number of patients who w 40 
had complete ventricular capture at each paced cycle (!) z 
length. Values for oral amiodarone at cycle lengths a: :r: of 275 and 250 ms are not shown because in only u 
one patient was there complete ventricular capture ~ 
at these cycle lengths. Statistical comparisons were 
20 performed with a paired t test. The percent changes 
in QRS duration after intravenous (IV) and oral 
amiodarone are compared with control and with 
each other. NS = not significant. 
0 
intervals that resulted in the induction of tachycardia in the 
control state no longer resulted in ventricular capture after 
intravenous amiodarone. Among the other five patients with 
inducible sustained ventricular tachycardia, the arrhythmia 
was of the same configuration as in the control study in 
three patients and of a different configuration in two. In the 
six patients who had inducible ventricular tachycardia after 
intravenous amiodarone, the ventricular tachycardia cycle 
length was unchanged in one, shortened in one and length•
ened in four patients (Table 3). 
The effects of oral amiodarone on ventricular tachycar•
dia induction were different from the effects of intravenous 
amiodarone. The three patients who had either non inducible 
or nonsustained ventricular tachycardia after intravenous 
amiodarone all had inducible sustained ventricular tachy•
cardia after oral amiodarone, as did three others (Table 3). 
In Patients 1 and 6, coupling intervals that resulted in ven•
tricular capture without ventricular tachycardia induction 
after intravenous amiodarone did result in tachycardia in•
duction after oral amiodarone (Fig. 4). Two patients had 
inducible nonsustained ventricular tachycardia (Fig. 5). In 
only four patients was the configuration of the induced ven•
tricular tachycardia after oral amiodarone the same as in the 
control study. In these patients, the coupling intervals of 
the extrastimuli that induced ventricular tachycardia were 
consistently 40 to 110 ms longer than the coupling intervals 
of the extrastimuli that induced tachycardia in the control 
state (Fig. 4). In every patient, the ventricular tachycardia 
cycle length was longer after oral amiodarone than in the 
control study (mean 336 ± 104 versus 240 ± 90 ms p < 
t 
* - p < 0.05 
t - P < 0.01 * - P < 0.001 
,...--, 
,...--, 
t 
,...--, 
t 
(6) 
NS 
~ 
NS 
(5) ,..---r 
(3) 
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0.001). There was no discernible relation between the ef•
fects of intravenous or oral amiodarone on the right ven•
tricular effective refractory period, intraventricular conduc•
tion and ventricular tachycardia induction. 
Relations among amiodarone, desethylamiodarone and 
reverse T 3 serum levels and electrophysiologic effects. In 
six patients (Cases 1 to 6), the QRS duration at comparable 
paced cycle lengths was greater after oral than after intra•
venous amiodarone. In each of these six patients, there was 
a large increase in the serum reverse T 3 to levels of 515 to 
1,545 pg/ml (Fig. 6). In contrast, in two patients (Cases 7 
and 8) the QRS duration at comparable paced cycle lengths 
was not greater after oral than after intravenous amiodarone, 
and in both of these patients the serum reverse T3 level, 
although increased from baseline, was still within normal 
limits (Fig. 6). There were no other discernible relations 
among the serum levels of amiodarone, desethylamiodarone 
or reverse T 3 and the electrophysiologic effects of intra•
venous or oral amiodarone. 
Discussion 
Relative effects of intravenous and oral amioda•
rone. Our results demonstrate that both intravenous and 
oral amiodarone prolong the ventricular effective refractory 
period and slow intraventricular conduction in a rate-de•
pendent fashion, but usually to different degrees. After 2 
months of oral amiodarone therapy, the ventricular effective 
refractory period is consistently prolonged by 30 to 80 ms 
beyond the 10 to 30 ms increase that occurs acutely after 
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Figure 3. Patient 8. The rate-dependent response of QRS duration 
to intravenous and chronic oral amiodarone therapy. Shown are 
the last two to three QRS complexes of a train of 15 to 20 paced 
complexes. In the control state, QRS duration was not rate de•
pendent; that is, QRS duration was 173 ms at paced cycle lengths 
of 600, 350 and 250 ms. After intravenous amiodarone, at a paced 
cycle length of 600 ms, there was a 12% increase in QRS duration 
to 193 ms. At paced cycle lengths of 350 and 275 ms, QRS duration 
increased by 20 (to 207 ms) and 31 % (to 227 ms), respectively. 
There was 2: 1 ventricular capture at a paced cycle length of 250 
ms after intravenous amiodarone. After 2 months of oral amio•
darone, there was 2: I ventricular capture at paced cycle lengths 
of 300 ms and less. At paced cycle lengths of 600 and 350 ms, 
the QRS duration was similar to the values obtained after intra•
venous amiodarone. The serum level of reverse triiodothyronine 
(T 3) was 250 pg/ml when intravenous amiodarone was tested and 
343 pg/ml when oral amiodarone was tested (nonnal range 80 to 
350 pg/ml). 
f-200ms--l 
intravenous amiodarone. In contrast, the rate-dependent 
slowing of intraventricular conduction that occurs acutely 
after intravenous amiodarone is not consistently accentuated 
after oral amiodarone. The variable response of ventricular 
refractoriness and intraventricular conduction to intravenous 
and oral amiodarone suggests that different mechanisms 
may underlie the relative effects of intravenous and oral 
amiodarone on refractoriness and conduction. 
EtTects on ventricular refractoriness. A prior study 
(23) suggested that amiodarone's electrophysiologic effects 
on the myocardium may be mediated by a disturbance in 
thyroid hormone metabolism. Prolongation of the QT in•
terval and suppression of ventricular premature depolari•
zations during treatment with oral amiodarone were found 
to correlate with elevation in the serum level of reverse T 3. 
An increase in the serum level of reverse T 3 during therapy 
Table 3. Effects of Intravenous and Oral Amiodarone Administration on the Induction of Ventricular Tachycardia 
Induced Ventricular Tachycardia 
Control Study Intravenous Amiodarone Oral Amiodarone 
Case Form CL (ms) No. of ES Form CL(ms) No. of ES Form CL (ms) No.ofES 
I RBBB 200 3 No VT Poly 300 2 
2 RBBB 190 3 RBBB* 230 2 RBBB 250 3 
3 RBBB 390 2 LBBB 360 2 LBBB 480 2 
4 Poly 150 2 Poly 180 2 Poly* 210 3 
5 Poly 200 3 LBBB 350 3 LBBB* 360 2 
6 LBBB 200 3 No VT LBBB 290 3 
7 RBBB 375 2 RBBB 420 2 RBBB 500 
8 RBBB 220 3 RBBB 230 3 LBBB 300 2 
*Only nonsustained ventricular tachycardia was inducible. CL = cycle length; ES = extrastlmuli; LBBB = left bundle branch block configuration; 
Poly = polymorphic; RBBB = right bundle branch block configuration; VT = ventncular tachycardia. 
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Figure 4. Patient 6. Results of programmed ventricular stimula•
tion after intravenous and chronic oral amiodarone therapy. Three 
electrocardiographic leads (V I, I and III) are shown. In the control 
state, sustained ventricular tachycardia, cycle length (CL) 200 ms, 
which had a left bundle branch block configuration and a superior 
axis, was induced by triple extrastimuli at the right ventricular 
outflow tract. Shown are the SISI/SIS2/S2S3/S3S4 coupling intervals 
that induced the ventricular tachycardia. After intravenous amio•
darone there was not complete ventricular capture at the same 
coupling intervals that had induced ventricular tachycardia in the 
control study, and ventricular tachycardia was not inducible. Shown 
are the shortest SISI/SIS2/S2S3/S3S4 coupling intervals that resulted 
in complete ventricular capture at the right ventricular outflow 
tract. Two repetitive complexes were induced, but not ventricular 
tachycardia. After 2 months of treatment with oral amiodarone, 
sustained ventricular tachycardia, cycle length 290 ms, again with 
a left bundle branch block configuration and a superior axis, was 
induced by triple extrastimuli at the right ventricular outflow tract. 
Note that the coupling intervals of the extrastimuli that induced 
ventricular tachycardia are considerably longer than in the control 
study. 
with amiodarone reflects a block in the peripheral conversion 
of tetraiodothyronine (T4) to T3 , and increased monode•
iodination of T 4 to reverse T 3 (24). However, in our study, 
the serum level of reverse T 3 was not always elevated above 
the normal range after 2 months of treatment with oral 
amiodarone. Therefore, the larger increase in the ventricular 
effective refractory period that occurs after 2 months of oral 
treatment with amiodarone compared with that after intra•
venous treatment is unlikely to be attributable to a distur•
bance in thyroid hormone metabolism. 
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Figure 5. Patient 5. Results of programmed ventricular stimula•
tion after intravenous and chronic oral amiodarone therapy. Shown 
are electrocardiographic leads V., I and III. In the control state, 
sustained polymorphic ventricular tachycardia, cycle length (CL) 
200 ms, was induced by triple extrastimuli at the right ventricular 
outflow tract. Shown are the SISI/SIS2/SzS3/S3S4 coupling intervals 
that induced the ventricular tachycardia. After intravenous amio•
darone, sustained ventricular tachycardia was still inducible with 
triple extrastimuli but was modified to have a left bundle branch 
block configuration, inferior axis and a cycle length of 350 ms. 
After 2 months of treatment with oral amiodarone, ventricular 
tachycardia was not inducible at a basic drive cycle length of 500 
ms. However, with a basic drive cycle length of 400 ms and double 
extrastimuli at the right ventricular outflow tract, nonsustained 
ventricular tachycardia (cycle length 360 ms, left bundle branch 
block configuration with an inferior axis) was reproducibly in•
duced. Triple extrastimuli also resulted in nonsustained ventricular 
tachycardia. 
Amiodarone has been demonstrated to acutely prolong 
action potential duration in a guinea pig papillary muscle 
preparation (25). The observation that intravenous amio•
darone significantly prolongs ventricular refractoriness sug•
gests that amiodarone also has a direct effect on action 
potential duration in ventricular myocardium in humans. 
Potentiation of this effect by oral amiodarone cannot be 
explained by differences in the serum level of amiodarone, 
because the amiodarone serum level was consistently higher 
during testing of intravenous amiodarone than during testing 
of oral amiodarone. Possible explanations for the greater 
increase in ventricular effective refractory period after oral 
compared with intravenous therapy include 1) a higher tissue 
level of amiodarone after long-term administration; 2) ac•
cumulation during chronic oral therapy of desethylamio•
darone, which is not detectable acutely after administration 
of intravenous amiodarone and which may have a direct 
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Figure 6. Relation between QRS prolongation by intravenous 
and chronic oral amiodarone therapy and the reVerse T 3 serum 
level in eight patients. On the ordinate is the percent change (over 
control) in the QRS duration measured at the same ventricular 
paced cycle length for both intravenous and oral amiodarone. The 
ventricular paced cycle length used was the shortest one resulting 
in complete ventricular capture after treatment with oral amioda•
rolle. Note that in two patients whose reverse T3 serum level was 
still within the normal range (80 to 350 pg/ml) after treatment with 
oral arhiodarone there was no appreciable augmentation of QRS 
prolongation by oral compared with intravenous amiodarone. Open 
circles = intravenous amiodarone; closed circles = oral 
amiodarone. 
electrophysiologic effect independent of amiodarone' s ef•
fects; and 3) a time-dependent factor in amiodarone's mem•
brane effects. 
Whereas prior studies (18,19) have demonstrated that 
intravenous amiodarone acutely prolongs refractoriness in 
the atrioventricular node and in accessory atrioventricular 
connections, an acute effect on ventricular refractoriness 
has not been previously demonstrated (15, 18, 19). However, 
prior studies utilized a dose of intravenous amiodarone of 
5 mg/kg, whereas a dose of 10 mg/kg was used in our study. 
Effects on intraventricular conduction. In an isolated 
papillary muscle preparation, amiodarone was found (25) 
to block sodium channels in a rate-dependent fashion and 
to thereby decrease the maximal rate of rise of the action 
potential upstroke. Because intraventricular conduttion de•
perlds predominantly on the fast sodium current, prolon•
gation of intraventricular conduction would also be expected 
to occur in a rate-dependent fashion. A rate-dependent pro•
longation of intraventricular conduction, as reflected by 
changes in Q}{S duration during ventricular pacing, was 
demonstrated in response to intravenous amiodarone in a 
prior study (20) and confirmed in the present study. This 
rate-dependent slowing of intraventricular conduction was 
markedly accentuated after long-term treatment with oral 
amiodarone in some patients, but not in others. Augmen-
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tation of the effects of amiodarone on intraventricular con•
duction after long-term therapy correlated not with the serum 
levels of amiodarone or desethylamiodarone, but with an 
elevation in the serum level of reverse T 3. In each patient 
whose reverse T3 serum level was elevated beyond the nor•
mal range after 2 months of treatment with amiodarone, 
slowing of intraventricular conduction was more pro•
nounced by oral than by intravenous amiodarone. In con•
trast, in both patients who had a normal serum level of 
reverse T 3 after 2 months of amiodarone therapy, the effects 
of oral amiodarone on intraventricular conduction were sim•
ilar to the effects of intravenous amiodarone. This suggests 
that the direct effects of amiodarone on intraventricular con•
duction may be potentiated indirectly by its effects on thy•
roid hormone metabolism. 
By blocking the peripheral conversion of T4 to T3, or by 
competing with T3 binding to nuclear receptor sites, or both, 
amiodarone (or desethylamiodarone) may induce a state of 
hypothyroidism (24,26). The principal electrophysiologic 
effect of hypothyroidism on the action potential is to prolong 
its duration (24). Prolongation of the action potential du•
ration (as might occur secondary to an amiodarone-induced 
disturbance in thyroid hortnone metabolism) would be ex•
pected to prolong the period during which sodium channels 
are inactivated. Mason et al. (25) demonstrated that amio•
darone blocks sodium channels that are in the inactivated 
state. To the extent that an increase in the serum level of 
reverse T 3 reflects a state of hypothyroidism induced by 
amiodarone, our results are consistent with potentiation of 
amiodarone's blockade of sodium channels by a chronic 
increase in action potential duration. Alternatively, the ap•
parent correlation between an elevated reverse T 3 serum 
level and potentiation of an acute rate-dependent slowing 
of intraventricular conduction by oral amiodarone may sim•
ply reflect two independent end-organ effects that become 
more pronounced during long-term amiodarone therapy in 
some patients but not in others. 
Effects on ventricular tachycardia induction. In the 
present study, intravenous amiodarone was found to be ca•
pable of either suppressing or modifying the induction of 
ventricular tachycardia by programmed stimulation. These 
results confirm the findings of Hariman et al. (15), who 
reported that intravenoUs amiodarone suppressed the induc•
tion of ventricular tachycardia in three of seven patients and 
converted sustained to nonsustained ventricular tachycardia 
in an additional two patients. The reason that amiodarone 
suppresses or modifies the induction of ventricular tachy•
cardia in some patients but not in others is not clear; there 
was no discernible relation between the absolute or relative 
effects of amiodarone on the right ventricular effective re•
fractory period or intraventricular conduction and its effects 
on the induction of ventricular tachycardia. However, any 
such conclusions are limited by the inability to determine 
amiodarone's effects on the actual substrate of the reentrant 
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circuit. Our present observations relate to refractoriness 
measured at the right ventricular apex and global intraven•
tricular conduction. The effects of amiodarone on conduc•
tion and refractoriness within the reentrant circuit respon•
sible for ventricular tachycardia could not be determined 
and may differ from its global effects. 
The effects of oral amiodarone on the induction of ven•
tricular tachycardia were discordant with the acute effects 
of intravenous amiodarone. In two patients in whom intra•
venous amiodarone completely suppressed the induction of 
ventricular tachycardia, sustained ventricular tachycardia was 
inducible after 2 months of oral treatment. Furthermore, in 
two patients who had inducible sustained ventricular tachy•
cardia after intravenous amiodarone, only nonsustained ven•
tricular tachycardia could be induced after oral treatment. 
These discordant responses to programmed stimulation are 
presumably due to a difference in the relative effects of 
intravenous and oral amiodarone on conduction and refrac•
toriness within the reentrant circuit responsible for ventric•
ular tachycardia. For example, induction of ventricular 
tachycardia after oral amiodarone by extrastimuli with cou•
pling intervals that did not result in induction of ventricular 
tachycardia after intravenous amiodarone may be attribut•
able to a greater degree of slowing of intraventricular con•
duction by oral amiodarone. Again, because the effects of 
amiodarone on the specific substrate for reentry were not 
determined, this explanation is speculative. 
Limitations. 1) Although the duration of the QRS com•
plex during ventricular pacing was used as an index of global 
intraventricular conductioh, this is not a direct measure of 
intraventricular conduction. 2) The diluent in the intrave•
nous form of amiodarone was Tween 80. The electrophysio•
logic effects of this diluent were not studied; therefore, its 
contribution to the changes observed after the administration 
of intravenous amiodarone is unknown. 
Conclusions. The acute and chronic effects of amio•
darone on ventricular refractoriness and conduction are dif•
ferent, perhaps because of a variable interplay between the 
direct and indirect effects of this agent on the myocardial 
action potential. Long-term amiodarone therapy results in 
a marked prolongation of ventricular refractoriness beyond 
the relatively small but significant increase that occurs acutely 
in response to intravenous amiodarone administration. This 
may reflect a direct effect of amiodarone that is accentuated 
by either higher tissue levels of amiodarone or accumulation 
of desethylamiodarone. Augmentation by oral amiodarone 
of the acute rate-dependent slowing of intraventricular con•
duction that occurs after intravenous administration appears 
to correlate with an increase in the serum level of reverse 
T3 , suggesting that effects on thyroid metabolism may po•
tentiate sodium channel blockade by amiodarone. Both in•
travenous and chronic oral amiodarone can suppress or mod•
ify ventricular tachycardia induced by programmed 
stimulation, but in a discordant fashion, probably because 
JACC Vol 7, No. I 
January 1986:148-57 
of different relative effects on conduction and refractoriness. 
Acute electrophanhacologic testing with intravenous amio•
darone therefore cantlot be used to predict the response to 
programmed ventricular stimulation after long-term amio•
darone therapy. 
We express our sincere appreciation to Lisa Hackbarth and Terri Glazier 
for excellent secretarial assistance, 
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